Fc-Engineered Anti-4-1BB Antibodies Pack a One-Two Punch

A key issue in immuno-oncology is how to optimize and combine antibody therapies for improved efficacy. In this issue of Immunity , Buchan et al. (2018) reveal the importance of antibody Fc region, Fc receptor availability, and sequence of administration for optimal cancer therapy with antibodies targeting the co-stimulatory receptor 4-1BB.